Form 4: Third Rock Ventures IV, L.P. Sells 75,000 Shares of Tango Therapeutics

Third Rock Ventures IV, L.P. disposed of 75,000 shares of Tango Therapeutics (TNGX) at an average price of $11.5618 on September 5, 2024.

Summary

• On September 5, 2024, Third Rock Ventures IV, L.P. sold 75,000 shares of Tango Therapeutics (TNGX) common stock.
• The sale was executed at a weighted average price of $11.5618 per share, with individual transactions ranging from $11.54 to $11.76.
• Following the transaction, Third Rock Ventures IV, L.P. directly holds 16,926,475 shares of Tango Therapeutics.
• Third Rock Ventures GP IV, L.P. is the general partner of TRV IV, and TRV GP IV, LLC is the general partner of TRV GP IV.
• Both TRV GP IV and TRV GP IV LLC disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine transaction disclosure. The sale of shares by a major holder could be perceived negatively, but without further context, it's a neutral event.

Negatives

• Third Rock Ventures IV, L.P., a significant shareholder, reduced its stake in Tango Therapeutics by selling 75,000 shares.

Risks

• The sale of shares by a major shareholder like Third Rock Ventures IV, L.P. could create downward pressure on the stock price.

Industry Context

Sales by major shareholders are common and can be for various reasons, including portfolio rebalancing or taking profits. The impact on the stock price depends on market perception and the overall health of the company.

Stakeholder Impact

• Shareholders may react to the news of a large shareholder selling shares, potentially impacting the stock price.

Key Dates